These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 15488559)

  • 1. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies.
    Bucerius J; Herkel C; Joe AY; Altehoefer C; Finke J; Moser E; Reinhardt MJ
    Nuklearmedizin; 2006; 45(3):105-10; quiz N25-6. PubMed ID: 16710505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
    Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
    Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P
    Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
    Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
    Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.